Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Cell-Penetrating Peptides with Unexpected Anti-Amyloid Properties
Stockholms universitet, Naturvetenskapliga fakulteten, Institutionen för biokemi och biofysik.ORCID-id: 0000-0003-0905-7911
Stockholms universitet, Humanistiska fakulteten, Institutionen för arkeologi och antikens kultur. CellPept Sweden AB, Sweden.ORCID-id: 0000-0001-6836-5610
Stockholms universitet, Naturvetenskapliga fakulteten, Institutionen för biokemi och biofysik. CellPept Sweden AB, Sweden.ORCID-id: 0000-0003-2187-1537
Rekke forfattare: 32022 (engelsk)Inngår i: Pharmaceutics, ISSN 1999-4923, E-ISSN 1999-4923, Vol. 14, nr 4, artikkel-id 823Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

Cell-penetrating peptides (CPPs) with sequences derived originally from a prion protein (PrP) have been shown to exhibit both anti-prion and anti-amyloid properties particularly against prion proteins and the amyloid-β (Aβ) peptide active in Alzheimer’s disease. These disease-modifying properties are so far observed in cell cultures and in vitro. The CPP sequences are composed of a hydrophobic signal sequence followed by a highly positively charged hexapeptide segment. The original signal sequence of the prion protein can be changed to the signal sequence of the NCAM1 protein without losing the anti-prion activity. Although the detailed molecular mechanisms of these CPP peptides are not fully understood, they do form amyloid aggregates by themselves, and molecular interactions between the CPPs and PrP/Aβ can be observed in vitro using various spectroscopic techniques. These initial intermolecular interactions appear to re-direct the aggregation pathways for prion/amyloid formation to less cell-toxic molecular structures (i.e., co-aggregates), which likely is why the disease-inducing PrP/Aβ aggregation is counteracted in vivo.

sted, utgiver, år, opplag, sider
2022. Vol. 14, nr 4, artikkel-id 823
Emneord [en]
protein aggregation, secretion signal peptide, peptide engineering, drug design
HSV kategori
Identifikatorer
URN: urn:nbn:se:su:diva-204559DOI: 10.3390/pharmaceutics14040823ISI: 000785290300001PubMedID: 35456657Scopus ID: 2-s2.0-85128454673OAI: oai:DiVA.org:su-204559DiVA, id: diva2:1657346
Tilgjengelig fra: 2022-05-10 Laget: 2022-05-10 Sist oppdatert: 2022-05-10bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Österlund, NicklasWärmländer, Sebastian K. T. S.Gräslund, Astrid

Søk i DiVA

Av forfatter/redaktør
Österlund, NicklasWärmländer, Sebastian K. T. S.Gräslund, Astrid
Av organisasjonen
I samme tidsskrift
Pharmaceutics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 34 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf